Acceptability and Tolerance Study of a High Energy Tube Feed With Food Derived Ingredients

Sponsor
Société des Produits Nestlé (SPN) (Industry)
Overall Status
Recruiting
CT.gov ID
NCT06034951
Collaborator
(none)
15
1
1
4.2
3.5

Study Details

Study Description

Brief Summary

Enterally fed adults and children who are assessed by the dietitian as requiring an adult high-energy, fibre-containing enteral formula will be recruited. Data from 15 participants are required in order to submit an application to the Advisory Committee on Borderline Substances (ACBS) for product registration.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Compleat 1.5 HP
N/A

Detailed Description

To evaluate the acceptability (including gastrointestinal tolerance and compliance) of a high energy, adult enteral formula with food-derived ingredients.This is a single arm, prospective, multi-centre study to evaluate the gastrointestinal tolerance and compliance over a 14-day period with the new tube feed.

Participants or their caregivers will be provided with 14-day supply of the new tube feed and will be asked to complete a daily diary and short questionnaire to record information allowing assessment of the following:

  • Gastrointestinal tolerance

  • Compliance with prescribed feed volume

Study Design

Study Type:
Interventional
Anticipated Enrollment :
15 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Acceptability (Including Gastrointestinal Tolerance and Compliance) of a High Energy, Adult Enteral Formula With Food-derived Ingredients.
Actual Study Start Date :
May 24, 2023
Actual Primary Completion Date :
Aug 21, 2023
Anticipated Study Completion Date :
Sep 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Other: Patients well established on tube feeds will act as their own control

These patients will switch from current to new tube feed to assess acceptability and tolerance

Dietary Supplement: Compleat 1.5 HP
Patients well established and stable on an enteral tube feed. This group will act as their own controls and switched to the new tube feed.

Outcome Measures

Primary Outcome Measures

  1. Daily patient diaries [14 days]

    Daily monitor of gastrointestinal tolerance using questionnaire on increase, decrease or no change

  2. Daily formula intake [14 days]

    mL per day

Eligibility Criteria

Criteria

Ages Eligible for Study:
15 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients requiring an enteral tube feed (taking > 60% of energy needs from their feeding tube) as part of their dietary management for disease related malnutrition

  • Children 15 years and over

  • Adults and children requiring an adult high-energy and fibre-containing formula, as assessed by the dietitian.

  • Patients well-established and stable on enteral feeding.

  • Willingly given, written, informed consent from patient or consultee

  • Willingly given, written assent (if appropriate).

Exclusion Criteria:
  • Inability to comply with the study protocol, in the opinion of the investigator

  • Children under 15 years of age

  • Patients receiving mechanical ventilation, sedation or inotropic support

  • Patients on total parenteral nutrition

  • Known food allergies to any ingredients (see ingredients list) or galactosaemia

  • Patients with significant renal or hepatic impairment

  • Patients with planned changes to medication or treatments during the study period which may alter gastrointestinal function (e.g. chemotherapy). Changes in medications or nutritional products during the study intervention must be documented.

  • Participation in another interventional study within 2 weeks of this study.

  • Patients with a clinical indication for a low fibre or fibre free diet as advised by the healthcare team.

  • Patients with known or suspected ileus or mechanical bowel obstruction

Contacts and Locations

Locations

Site City State Country Postal Code
1 Martha Van Der Linde Worcester United Kingdom

Sponsors and Collaborators

  • Société des Produits Nestlé (SPN)

Investigators

  • Principal Investigator: Martha Van Der Linde, Community Paediatric Dietitian Worcestershire North Nutrition and Dietetic Hastings Way, Worcester. UK
  • Principal Investigator: Amy Carter, The Walton Centre NHS Foundation Trust, Liverpool UK
  • Principal Investigator: Sam Ogundere, Lewisham and Greenwich NHS Trust London UK
  • Principal Investigator: Adrian Gilson, Newham General Hospital London UK

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Société des Produits Nestlé (SPN)
ClinicalTrials.gov Identifier:
NCT06034951
Other Study ID Numbers:
  • Compleat002
First Posted:
Sep 13, 2023
Last Update Posted:
Sep 13, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Sep 13, 2023